Importantly, therapeutic modalities targeting CXCL13-CXCR5 signaling in the tumor microenvironment are currently being explored, although no small molecule pharmacological inhibitors directly targeting CXCL13 or CXCR5 have been yet developed. Here, CXCR5 is linked to neoplasm.